Contributions
Abstract: PB1781
Type: Publication Only
Background
Hairy cell leukemia (HCL) accounts for approximately 2% of all leukemias and is associated with pancytopenia, splenomegaly, and recurrent infections. Therapy with the purine analogues cladribine (2CdA) or pentostatin (2’deoxycoformycin), has been most effective and both agents have achieved equivalent results in HCL. In this regard cladribine given as a single course, achieves a high response rate. Several alternative dosing schedules have been reported for 2CdA including subcutaneous (SC) or intravenous (IV) delivery, either as a “fixed daily dose” or “weight based dose” for 5 or 7 days.
Aims
In this retrospective study, we have summarized the Israeli experience with HCL over the past 30 years, and analyzed demographic data, relevant laboratory and clinical parameters with special emphasis on outcome after first line treatment with cladribine.
Methods
We collected retrospective data on patients with HCL from 12 medical centers in Israel, followed and treated during 1985-2015. The study was approved l by local institutional IRBs of each medical center
Results
Data from the medical records of 202 patients with HCL was summarized. Mean follow up was 7.5 years (0.1-40), with a 5 and 10 years’ overall survival of 96% and 90.62% respectively. The median age at diagnosis was 53 years, and most (81.77%). were males
Conclusion
This study is the first comprehensive summary of the national Israeli experience involving a large cohort of HCL patients with long follow up. These results serve as validation of
Session topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical
Keyword(s): Hairy cell leukemia, Cladribine
Abstract: PB1781
Type: Publication Only
Background
Hairy cell leukemia (HCL) accounts for approximately 2% of all leukemias and is associated with pancytopenia, splenomegaly, and recurrent infections. Therapy with the purine analogues cladribine (2CdA) or pentostatin (2’deoxycoformycin), has been most effective and both agents have achieved equivalent results in HCL. In this regard cladribine given as a single course, achieves a high response rate. Several alternative dosing schedules have been reported for 2CdA including subcutaneous (SC) or intravenous (IV) delivery, either as a “fixed daily dose” or “weight based dose” for 5 or 7 days.
Aims
In this retrospective study, we have summarized the Israeli experience with HCL over the past 30 years, and analyzed demographic data, relevant laboratory and clinical parameters with special emphasis on outcome after first line treatment with cladribine.
Methods
We collected retrospective data on patients with HCL from 12 medical centers in Israel, followed and treated during 1985-2015. The study was approved l by local institutional IRBs of each medical center
Results
Data from the medical records of 202 patients with HCL was summarized. Mean follow up was 7.5 years (0.1-40), with a 5 and 10 years’ overall survival of 96% and 90.62% respectively. The median age at diagnosis was 53 years, and most (81.77%). were males
Conclusion
This study is the first comprehensive summary of the national Israeli experience involving a large cohort of HCL patients with long follow up. These results serve as validation of
Session topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical
Keyword(s): Hairy cell leukemia, Cladribine